<DOC>
	<DOCNO>NCT00510406</DOCNO>
	<brief_summary>The study examine efficacy , safety tolerability combination therapy tamsulosin solifenacin compare placebo monotherapy tamsulosin solifenacin treatment male LUTS associate BPH .</brief_summary>
	<brief_title>A Study With Combination Treatment ( Tamsulosin Hydrochloride Solifenacin Succinate ) Male Patients With LUTS/BPH</brief_title>
	<detailed_description>Placebo Solifenacin succinate Tamsulosin hydrochloride Tamsulosin hydrochloride + solifenacin succinate The primary comparison combination treatment tamsulosin hydrochloride monotherapy . Other comparison : Placebo combination treatment . Solifenacin monotherapy combination treatment</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>male patient LUTS associate BPH diagnose &gt; 3 month IPSS score &gt; 13 void storage symptom maximum flow rate &gt; 4 mL/s &lt; 15 mL/s post void residual volume &gt; 200 mL symptomatic urinary tract infection</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Lower Urinary Tract Symptoms</keyword>
	<keyword>Treatment</keyword>
	<keyword>Solifenacin succinate</keyword>
	<keyword>Tamsulosin hydrochloride</keyword>
	<keyword>Prostatic Hyperplasia</keyword>
</DOC>